PT - JOURNAL ARTICLE AU - Mohammad Tarek AU - Mahmoud Elhefnawi AU - Juliana Terzi Maricato AU - Ricardo Sobhie Diaz AU - Iart Luca Shytaj AU - Andrea Savarino TI - Custommune: a web tool to design personalized and population-targeted vaccine epitopes AID - 10.1101/2020.04.25.20079426 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.25.20079426 4099 - http://medrxiv.org/content/early/2020/04/29/2020.04.25.20079426.short 4100 - http://medrxiv.org/content/early/2020/04/29/2020.04.25.20079426.full AB - Computational prediction of immunogenic epitopes is a promising platform for therapeutic and preventive vaccine design. A potential target for this strategy is human immunodeficiency virus (HIV-1), for which, despite decades of efforts, no vaccine is available. In particular, a therapeutic vaccine devised to eliminate infected cells would represent a key component of cure strategies. HIV peptides designed based on individual viro-immunological data from people living with HIV/AIDS have recently shown able to induce post-therapy viral set point abatement. However, the reproducibility and scalability of this method is curtailed by the errors and arbitrariness associated with manual peptide design as well as by the time-consuming process.We herein introduce Custommune, a user-friendly web tool to design personalized and population-targeted vaccines. When applied to HIV-1, Custommune predicted personalized epitopes using patient specific Human Leukocyte Antigen (HLA) alleles and viral sequences, as well as the expected HLA-peptide binding strength and potential immune escape mutations. Of note, Custommune predictions compared favorably with manually designed peptides administered in a recent phase II clinical trial (NCT02961829).Furthermore, we utilized Custommune to design preventive vaccines targeted for populations highly affected by COVID-19. The results allowed the identification of peptides tailored for each population and predicted to elicit both CD8+ T-cell immunity and neutralizing antibodies against structurally conserved epitopes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).Overall, our data describe a new tool for rapid development of personalized or population-based immunotherapy against chronic and acute viral infections.Competing Interest StatementMT, MEH, ILS, RD and AS have requested patent rights on Custommune and/or personalized HIV-1 vaccine design strategies.Funding StatementMEH acknowledges support from the National Research Centre, and the Science and Technology Development Fund (STDF), Ministry of Higher Education and Scientific Research Cairo, Egypt (Grant 25632). RSD acknowledges support from the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP; 2013/11323-5) and the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq; 454700/2014-8).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe Custommune platform is available at http://www.custommune.com. Data used for multiple sequence alignment were retrieved from NCBI (https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/) and GISAID (https://www.gisaid.org). The structures used for homology modelling or molecular docking were retrieved from the pHLA3D database (https://www.phla3d.com.br) and the Protein Data Bank (https://www.rcsb.org). Allele frequencies were retrieved from the Allele Frequency Net Database (http://www.allelefrequencies.net/hla.asp). http://www.custommune.com https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/ https://www.gisaid.org https://www.phla3d.com.br https://www.rcsb.org http://www.allelefrequencies.net/hla.asp